about
Identification and characterization of nucleolin as a COUP-TFII coactivator of retinoic acid receptor β transcription in breast cancer cellsRegulation of BRCA2 gene expression by the SLUG repressor protein in human breast cellsThe hyaluronan receptors CD44 and Rhamm (CD168) form complexes with ERK1,2 that sustain high basal motility in breast cancer cellsDown-regulation of UCRP and UBE2L6 in BRCA2 knocked-down human breast cellsAntigen-specific T cells: analyses of the needles in the haystackThe ALTERNATE trial: assessing a biomarker driven strategy for the treatment of post-menopausal women with ER+/Her2- invasive breast cancerSustained proliferation in cancer: Mechanisms and novel therapeutic targetsAssociation of common variants in mismatch repair genes and breast cancer susceptibility: a multigene study.Akt2 inhibition enables the forkhead transcription factor FoxO3a to have a repressive role in estrogen receptor alpha transcriptional activity in breast cancer cells.The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell linesAn Activin A/BMP2 chimera, AB215, blocks estrogen signaling via induction of ID proteins in breast cancer cells.Proteomic snapshot of breast cancer cell cycle: G1/S transition point.Most basal-like breast carcinomas demonstrate the same Rb-/p16+ immunophenotype as the HPV-related poorly differentiated squamous cell carcinomas which they resemble morphologically.Upregulation of Claudin-4, CAIX and GLUT-1 in distant breast cancer metastases.Protein kinase D1 regulates ERα-positive breast cancer cell growth response to 17β-estradiol and contributes to poor prognosis in patientsThe Effects of 17β-estradiol in Cancer are Mediated by Estrogen Receptor Signaling at the Plasma Membrane.FOXK2 transcription factor suppresses ERα-positive breast cancer cell growth through down-regulating the stability of ERα via mechanism involving BRCA1/BARD1.P2Y2 receptor activation by nucleotides released from highly metastatic breast cancer cells increases tumor growth and invasion via crosstalk with endothelial cells.PinX1: a sought-after major tumor suppressor at human chromosome 8p23Atrophic vaginitis in breast cancer survivors: a difficult survivorship issue.Estrogen transactivates EGFR via the sphingosine 1-phosphate receptor Edg-3: the role of sphingosine kinase-1Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.Progestin modulates the lipid profile and sensitivity of breast cancer cells to docetaxelNovel identification of UDP-glucuronosyltransferase 1A10 as an estrogen-regulated target gene.Forkhead box transcription factor FOXO3a suppresses estrogen-dependent breast cancer cell proliferation and tumorigenesisAssessment of progesterone receptors in breast carcinoma by PET with 21-18F-fluoro-16α,17α-[(R)-(1'-α-furylmethylidene)dioxy]-19-norpregn-4-ene-3,20-dione.Epidermal growth factor induces G protein-coupled receptor 30 expression in estrogen receptor-negative breast cancer cells.Molecular diagnostic testing in malignant gliomas: a practical update on predictive markers.Regulation of constitutive and inducible AHR signaling: complex interactions involving the AHR repressorActivation of aromatase expression by retinoic acid receptor-related orphan receptor (ROR) alpha in breast cancer cells: identification of a novel ROR response element.Estrogen receptor β isoform 5 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis through interaction with Bcl2L12.Functional analysis of familial Asp67Glu and Thr1051Ser BRCA1 mutations in breast/ovarian carcinogenesis.Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway.Prolactin suppresses a progestin-induced CK5-positive cell population in luminal breast cancer through inhibition of progestin-driven BCL6 expression.Tamoxifen synergizes with 4-(E)-{(4-hydroxyphenylimino)-methylbenzene, 1,2-diol} and 4-(E)-{(p-tolylimino)-methylbenzene-1,2-diol}, novel azaresveratrol analogs, in inhibiting the proliferation of breast cancer cells.Inhibition of CDK8 mediator kinase suppresses estrogen dependent transcription and the growth of estrogen receptor positive breast cancer.Progesterone receptor-B regulation of insulin-like growth factor-stimulated cell migration in breast cancer cells via insulin receptor substrate-2.Issues and updates: evaluating estrogen receptor-alpha, progesterone receptor, and HER2 in breast cancer.Predictive markers in elderly patients with estrogen receptor-positive breast cancer treated with aromatase inhibitors: an array-based pharmacogenetic study.Role of cytochrome P450 genes in breast cancer etiology and treatment: effects on estrogen biosynthesis, metabolism, and response to endocrine therapy.
P2860
Q21090900-31DE8497-E7D0-4B9A-9A04-8E195ADD2CEDQ24595138-ACBC3998-B666-4845-AD10-90E55EBE772EQ24595836-6047F288-E378-4CEE-B46C-EB511B095427Q24603819-70B33DBA-15A9-40FC-883C-271043D7C76CQ24800475-C3749757-368A-4844-A7AF-6A10BC3D9BC3Q26786704-40DCB289-8630-4879-8B5E-E015DDB4038AQ28396388-541313B2-E8D6-4CF8-B3F7-1598E0FC4278Q33506772-2141FF1D-8FFF-4E19-ABEA-EF7871D225B2Q33614071-E52411A9-98F3-4F4A-BDE3-42CEF9B585FDQ33732552-EEE7EA35-646C-4609-94B9-F55AC5657A21Q34006810-38506013-648D-43AB-A7BE-F5A86CA0F7E4Q34010320-0FE7B961-63D1-4E5F-951F-2B17194645CEQ34248718-883DF1A7-0E23-422E-A260-285F5491F7FDQ34584209-0586453C-74BC-4E8A-8716-AD3D1D581D0EQ34998421-E2AD831E-5625-477C-9BBA-CA3613E3E0A1Q35084708-E34D3D66-C2B9-4E2C-9686-26AA259A61E6Q35148809-216C5290-A08B-4037-964C-C95D6BC4F121Q35521224-3E5D9D5A-2BB7-48EC-BACA-9A10BBDE8F58Q35640161-B3B57BDF-DCD5-4B27-B076-C1C694ED7375Q35824414-ECF4EBDE-991A-4F93-8BDA-A54769D11088Q36117441-2D702E2B-81D9-4B59-AFD9-2B12015C5B24Q36147459-38A9A7B6-AC3F-423F-AB4D-FF980BB2195BQ36350991-B99AB69F-B9BB-4675-9BA4-5CCE53126D89Q36453603-EA0E9B1D-D5C8-414E-89AE-7FAD039911B4Q36643119-AEA4C541-A80C-4B95-B337-0FBDF204F2E4Q36676997-589A9985-79F4-4CBA-8FA4-66F4F5AD1690Q36796668-BF5AA4FD-11EF-4C57-B261-EC60CF453677Q37037132-0020BD19-30E6-4BEE-B264-04EF079B3C26Q37240043-C228001A-8490-4728-94AF-081298D34A15Q37285287-24519C67-FDF3-4258-B55F-851C94C80864Q37382513-AD3DDFB3-BB40-40CC-92E6-2E9FFC1BF5E5Q37403022-88958F29-E158-47CB-BFE5-3D78CC8F2C42Q37515474-95FCABC2-CAA6-4243-8AC1-4C884CB32C65Q37554700-4A6C5A9F-C5DE-425B-A20A-81AAE08F32EFQ37588360-00D1C433-199D-42A5-8435-5A1C6FF34709Q37706453-74FD8C2F-E29A-489D-8D20-5568D36B4BC7Q37725048-DB390AFC-5D03-4908-803F-E51940E81D22Q37740951-2BB84D4D-1075-422D-93AC-4929AF2BD291Q38295718-9FB8B93A-0E08-4A2E-A304-632EF284DE4DQ38305705-78DA9C30-4C40-4E5E-9D8C-D3CC5A0BAC3C
P2860
description
2003 nî lūn-bûn
@nan
2003 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The biology of breast carcinoma.
@ast
The biology of breast carcinoma.
@en
type
label
The biology of breast carcinoma.
@ast
The biology of breast carcinoma.
@en
prefLabel
The biology of breast carcinoma.
@ast
The biology of breast carcinoma.
@en
P356
P1433
P1476
The biology of breast carcinoma.
@en
P2093
Nancy E Davidson
P304
P356
10.1002/CNCR.11126
P407
P433
P577
2003-02-01T00:00:00Z